Literature DB >> 15292688

Elevated epsilon-(gamma-glutamyl)lysine in human diabetic nephropathy results from increased expression and cellular release of tissue transglutaminase.

A M El Nahas1, H Abo-Zenah, N J Skill, S Bex, G Wild, M Griffin, T S Johnson.   

Abstract

INTRODUCTION: Diabetic nephropathy (DN) is the leading cause of chronic kidney failure, however the mechanisms underlying the characteristic expansion of the extracellular matrix (ECM) in diabetic kidneys remain controversial and unclear. In non-diabetic kidney scarring the protein crosslinking enzyme tissue transglutaminase (tTg) has been implicated in this process by the formation of increased epsilon-(gamma-glutamyl)lysine bonds between ECM components in both experimental and human disease. Studies in db+/db+ diabetic mice and in streptozotocin-treated rats have suggested a similar mechanism, although the relevance of this to human disease has not been addressed.
METHODS: We have undertaken a retrospective analysis of renal biopsies from 16 DN patients with type 2 diabetes mellitus using an immunohistochemical and immunofluorescence approach, with tTg and epsilon-(gamma-glutamyl)lysine crosslink quantified by confocal microscopy.
RESULTS: Immunofluorescent analysis of human biopsies (confocal microscopy) showed increases in levels of tTg (+1,266%, p < 0.001) and epsilon-(gamma-glutamyl)lysine (+486%, p < 0.001) in kidneys with DN compared to normal. Changes were predominantly in the extracellular periglomerular and peritubular areas. tTg staining correlated with epsilon-(gamma-glutamyl)lysine (r = 0.615, p < 0.01) and renal scarring (Masson's trichrome, r = 0.728, p < 0.001). Significant changes in epsilon-(gamma-glutamyl)lysine were also noted intracellularly in some (< or =5%) tubular epithelial cells. This is consistent with cells undergoing a novel transglutaminase-mediated cell death process in response to Ca2+ influx and subsequent activation of intracellular tTg.
CONCLUSION: Changes in tTg and epsilon-(gamma-glutamyl)lysine occur in human DN. Cellular export of tTg may therefore be a factor in the perpetuation of DN by crosslinking and stabilisation of the ECM, while intracellular activation may lead to cell death contributing towards tubular atrophy. Copyright 2004 S. Karger AG, Basel

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15292688     DOI: 10.1159/000078639

Source DB:  PubMed          Journal:  Nephron Clin Pract        ISSN: 1660-2110


  14 in total

1.  Tissue transglutaminase inhibits the TRPV5-dependent calcium transport in an N-glycosylation-dependent manner.

Authors:  Sandor Boros; Qi Xi; Henrik Dimke; Annemiete W van der Kemp; Kukiat Tudpor; Sjoerd Verkaart; Kyu Pil Lee; René J Bindels; Joost G Hoenderop
Journal:  Cell Mol Life Sci       Date:  2011-09-28       Impact factor: 9.261

2.  Syndecan-4 knockout leads to reduced extracellular transglutaminase-2 and protects against tubulointerstitial fibrosis.

Authors:  Alessandra Scarpellini; Linghong Huang; Izhar Burhan; Nina Schroeder; Muriel Funck; Timothy S Johnson; Elisabetta A M Verderio
Journal:  J Am Soc Nephrol       Date:  2013-12-19       Impact factor: 10.121

3.  Network Pharmacology-Based Exploration of the Therapeutic Mechanisms of Cordyceps cicadae in Renal Ischemia/Reperfusion.

Authors:  Jiajun Dong; Mingyang Cao; Hui Yu; Yang Dong; Conghui Han
Journal:  Ann Transplant       Date:  2022-09-30       Impact factor: 1.479

4.  Tissue transglutaminase contributes to interstitial renal fibrosis by favoring accumulation of fibrillar collagen through TGF-beta activation and cell infiltration.

Authors:  Nasim Shweke; Nada Boulos; Chantal Jouanneau; Sophie Vandermeersch; Gerry Melino; Jean-Claude Dussaule; Christos Chatziantoniou; Pierre Ronco; Jean-Jacques Boffa
Journal:  Am J Pathol       Date:  2008-08-07       Impact factor: 4.307

5.  Advanced glycation end products increase transglutaminase activity in primary porcine tenocytes.

Authors:  Ann K Rosenthal; Claudia M Gohr; Elizabeth Mitton; Vincent Monnier; Todd Burner
Journal:  J Investig Med       Date:  2009-02       Impact factor: 2.895

6.  Transglutaminase activation in neurodegenerative diseases.

Authors:  Thomas M Jeitner; Nancy A Muma; Kevin P Battaile; Arthur Jl Cooper
Journal:  Future Neurol       Date:  2009-07-01

7.  Upregulation of transglutaminase and ε (γ-glutamyl)-lysine in the Fisher-Lewis rat model of chronic allograft nephropathy.

Authors:  Badri Shrestha; Imran Butt; Michelle Da Silva; Armando Sanchez-Lara; Bart Wagner; Andrew Raftery; Timothy Johnson; John Haylor
Journal:  Biomed Res Int       Date:  2014-07-21       Impact factor: 3.411

8.  Monocytic Tissue Transglutaminase in a Rat Model for Reversible Acute Rejection and Chronic Renal Allograft Injury.

Authors:  Anna Zakrzewicz; Srebrena Atanasova; Winfried Padberg; Veronika Grau
Journal:  Mediators Inflamm       Date:  2015-04-30       Impact factor: 4.711

Review 9.  Spotlight on the Transglutaminase 2-Heparan Sulfate Interaction.

Authors:  Giulia Furini; Elisabetta A M Verderio
Journal:  Med Sci (Basel)       Date:  2019-01-04

10.  Restoration of renal TIMP3 levels via genetics and pharmacological approach prevents experimental diabetic nephropathy.

Authors:  Viviana Casagrande; Giulia Iuliani; Stefano Menini; Giuseppe Pugliese; Massimo Federici; Rossella Menghini
Journal:  Clin Transl Med       Date:  2021-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.